Immune Reconstitution in Children and Adolescents with High Risk Sickle Cell Disease (SCD) after Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback (Ind 14359)

Authors

Yaya Chu, New York Medical CollegeFollow
James Verbsky
Julie-An M. Talano
Erin Morris
Janet Ayello, New York Medical CollegeFollow
Carolyn Keever-Taylor
Lee Ann Baxter-Lowe
Rona S. Weinberg
Mildred Semidei-Pomales
Qiuhu Shi, New York Medical CollegeFollow
Theodore B. Moore
Sandra Fabricatore
Brenda Grossman
Shalini Shenoy
Mitchell S. Cairo, New York Medical CollegeFollow

Document Type

Abstract

Publication Date

3-2018

Journal Title

Biology of Blood and Marrow Transplantation

Department

Pediatrics

Second Department

Public Health

Third Department

Biostatistics

Recommended Citation

Chu, Y., Verbsky, J., Talano, J. M., Morris, E., Ayello, J., Keever-Taylor, C., Baxter-Lowe, L., Weinberg, R. S., Semidei-Pomales, M., Shi, Q., Moore, T. B., Fabricatore, S., Grossman, B., Shenoy, S., & Cairo, M. S. (2018). Immune Reconstitution in Children and Adolescents with High Risk Sickle Cell Disease (SCD) after Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback (Ind 14359). Biology of Blood and Marrow Transplantation, 24 (3 Suppl.1), S361-S362. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/228